Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2/3 Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia Refractory to or Ineligible for Immunosuppressive Therapy

Next Previous
Trial Profile

Phase 2/3 Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia Refractory to or Ineligible for Immunosuppressive Therapy

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Romiplostim (Primary)
  • Indications Aplastic anaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Kyowa Kirin

    • Most Recent Events

    • 25 Sep 2023 According to a Kyowa Kirin International media release, the company has received approval from the Japanese Ministry of Health, Labour and Welfare for hematopoietic stimulating agent Romiplate, to change the approved indication from "aplastic anemia (AA) in patients who had an inadequate response to conventional therapy" to "AA" in Japan.
    • 01 Jan 2021 Status changed from active, no longer recruiting to completed, according to Results published in the British Journal of Haematology.
    • 18 Jun 2019 According to a Kyowa Hakko Kirin media release, the company announced that it has received the partial change approval of Romiplate for an additional indication of treatment of aplastic anemia (AA) in patients who have had an inadequate response to conventional therapy from Japan's Ministry of Health, Labour and Welfare (MHLW).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top